Short News



short news

EMMJ6 at Shiraz in
Mid February 2015

SHIRAZ: IRAN: According to a message received from Prof. Farhad Handjani President-elect of Eastern Mediterranean Association of Medical Editors (EMAME) the EMMJ6 Medical Journals conference will be held at Shiraz in the second week of February 2015. The exact dates will be decided shortly.
The meeting will be organized by Shiraz University of Medical Sciences in collaboration with WHO and ISC besides contacts are also being established to have collaboration and speakers from EASE, EMWA, APAME and Elsevier, Hindawi, Medknow besides other organizations and institutions.

MI clinical trial participants
may have lower risk profile
than real-world MI patients

According to Research Letter published on Aug. 27 in the Journal of the American Medical Association, “individuals who participate in clinical trials typically have a lower risk profile and better prognosis compared with the real-world population of MI patients.” What’s more, even though “as many as two-thirds of patients in the National Cardiovascular Data Registry (NCDR) Coronary Treatment and Intervention Outcomes Network Registry were potentially eligible for clinical trials,” but “only 2.8% of patients participated in a research study.” The study authors “also observed declining participation in clinical trials among eligible participants, with 5.2% of eligible patients enrolled in trials in 2008, 4.4% in 2009, 3.8% in 2010, and 3.4% in 2011.” The study’s lead author was the recipient of honoraria from the American College of Cardiology Foundation.
CardioSource reports that data from the American College of Cardiology’s ACTION Registry-Get with the Guidelines was used to evaluate “whether participants in cardiovascular trials are representative of contemporary patients with MI.”

  “Modest” rise in number of
patients prescribed statins

According to a study published online in the Journal of the American College of Cardiology, “controversial lipid guidelines that nixed LDL cholesterol targets more closely matched statin prescribing to plaque burden compared with older guidance, leading to only a ‘modest’ rise in the number of patients prescribed Statins.” The 3,076-patient study revealed that “the likelihood of being prescribed a Statins rose with increasing plaque burden under the new AHA/ACC Guidelines on the Assessment of Cardiovascular Risk (GACR) compared with the 2001 National Cholesterol Education Program’s (NCEP) Adult Treatment Panel III (ATP-3) recommendations.” Researchers “found that 59% of patients with 50% or more stenosis of the left main coronary artery identified by CT angiogram and 40% of patients with 50% or more stenosis of other branches would not have been prescribed a Statins under the ATP-3 guidance,” whereas “the comparable results for the ACC/AHA guidelines were 19% and 10%, respectively.”

New guidelines may change
way physicians help patients
prevent heart attacks

“New guidelines issued in recent months from the American Heart Association and American College of Cardiology may be changing the way that doctors help patients prevent heart attacks and keep their cholesterol down.” Last November, “the American Heart Association and American College of Cardiology released new cardiovascular prevention guidelines addressing four areas that have an impact on heart-health: lifestyle, cholesterol, obesity and risk assessment.” Now, “one of the biggest changes in the cholesterol guidelines could lead more people to take Statins,” including people at high risk for a heart attack or stroke.

  Post-MI patients taking polypill may
have better medication adherence

According to trial results published online in the Journal of the American College of Cardiology and presented at the European Society of Cardiology meeting, “in the FOCUS (Fixed-Dose Combination Drug for Secondary Cardiovascular Prevention) series of studies, post-MI patients who were taking the polypill – a combination of aspirin, a statin, and an ACE inhibitor – had significantly greater medication adherence than those taking the three pills separately.” In addition, the 2,118-patient study revealed that “a younger age, depression, and a complex treatment regimen were significantly associated with a lack of adherence.”
“Moving forward, the researchers plan to evaluate the potential benefit of another polypill for the reduction of major adverse cardiovascular events (death from cardiovascular causes, nonfatal MI, stroke and revascularization) in an adequately powered outcomes trial.”

Potassium consumption tied to fewer
strokes in postmenopausal women

According to reports “aging women whose diets are rich in potassium are less likely to suffer strokes and die than women who have less of the mineral in their diets.” For the study, researchers “tracked 90,137 postmenopausal women ages 50 to 79 over 11 years to determine how much potassium the women consumed and whether they suffered strokes or died.” Researchers found that “women who consumed the highest amounts of potassium reduced their risk of stroke in general by 12 percent.” The study “was released online Sept. 4 in advance of print publication in the journal Stroke.”
The study “also found that in general,” many older women get “well below the recommended daily allowance of potassium. In the United States, this is 4700 mg.” The study’s senior author “pointed out that it is easily possible to get enough potassium in the diet just by increasing the consumption of fruit and vegetables.” For example, dietary sources rich in potassium include orange juice, bananas, potatoes, raisins, apricots, salmon, spinach, yogurt and white beans.

© Professional Medical Publications. All rights reserved.